Back
Exelixis 10K Form
Buy
86
EXEL
Exelixis
Last Price:
35.06
Seasonality Move:
12.94%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-04-30 | 10Q | EXEL/Exelixis Quarterly |
| 2023-11-01 | 10Q | EXEL/Exelixis Quarterly |
| 2023-08-01 | 10Q | EXEL/Exelixis Quarterly |
| 2023-05-09 | 10Q | EXEL/Exelixis Quarterly |
| 2022-11-01 | 10Q | EXEL/Exelixis Quarterly |
| 2022-08-09 | 10Q | EXEL/Exelixis Quarterly |
Receive EXEL News And Ratings
See the #1 stock for the next 7 days that we like better than EXEL
EXEL Financial Statistics
Sales & Book Value
| Annual Sales: | $1.83B |
|---|---|
| Cash Flow: | $262.14M |
| Price / Cash Flow: | 26.65 |
| Annual Sales: | $7.96 |
| Price / Book: | 4.5 |
Profitability
| EPS (TTM): | 1.56000 |
|---|---|
| Net Income (TTM): | $466.92M |
| Gross Margin: | $1.76B |
| Return on Equity: | 20.97% |
| Return on Assets: | 16.15% |
Exelixis Earnings Forecast
Key Exelixis Financial Ratios
- The Gross Profit Margin over the past 25 years for EXEL is 96.04%.
- The Selling, General & Administrative Expenses for EXEL have been equal to 29.65% of Gross Profit Margin.
- The Research & Development expenses have been 57.05% of Revenue.
- The Interest Expense is 0.00% of Operating Income.
- The Net Earning history of EXEL is 11.35% of Total Revenues.
- Per Share Earnings over the last 26 years have been positive in 16 years.
Exelixis Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | EXEL |
| CUSIP: | 30161Q |
| Website: | exelixis.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 3.93 |
| Quick Ratio: | 3.7 |
Price-to-Earnings
| Trailing P/E Ratio: | 55.15 |
|---|---|
| Forward P/E Ratio: | 18.27 |